102 cases of sensitization to an antiseptic containing chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol with different profiles of sensitization in adults and children

BACKGROUND

An aqueous antiseptic containing "chlorhexidine digluconate /benzalkonium chloride /benzyl alcohol" (CBB) is widely used in France. The only previous documented study dealing with allergic contact dermatitis to this antiseptic is one small case series in children. The French Vigilance Network for Dermatology and Allergy (REVIDAL-GERDA) has collected many cases in the last few years.

OBJECTIVES

To evaluate the clinical and sensitization profiles of patients diagnosed with allergic contact dermatitis to CBB.

METHODS

We performed a retrospective study of patients with contact dermatitis to CBB and positive tests to CBB and/or at least one of its components. All patients had to be tested with all components of CBB.

RESULTS

Seventy-one adults and thirty-one children were included. The lesions were extensive in 63 % of patients and 55% had delayed time to diagnosis. CBB patch tests were positive in 93.8% of cases. The allergen was identified in 97% of patients, mainly benzyl alcohol in adults (81.7%), and chlorhexidine digluconate in children (54.8%). 32.4% of the patients were sensitized to several components.

CONCLUSION

CBB is a cause of allergic contact dermatitis at all ages. The antiseptic's components should be tested. The sensitization profile seems to be different between adults and children. This article is protected by copyright. All rights reserved.